Research programme: RetroMetabolic therapeutics - ARYx

Drug Profile

Research programme: RetroMetabolic therapeutics - ARYx

Alternative Names: ATI-20,000; ATI-24,000

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator ARYx Therapeutics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Gastrointestinal disorders; Metabolic disorders

Most Recent Events

  • 24 Apr 2008 A lead candidate from this programme has entered clinical development
  • 20 Dec 2007 Preclinical trials in Psychotic disorders in USA (unspecified route)
  • 10 Nov 2006 Preclinical trials in Asthma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top